4.7 Article

Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study

Ismael Fernandez-Miranda et al.

Summary: This study examined the significance of circulating tumor DNA (ctDNA) in predicting response to therapy and early disease progression in follicular lymphoma (FL) patients. The results showed that baseline ctDNA levels are associated with early disease progression and treatment response in FL.

CLINICAL CANCER RESEARCH (2023)

Review Medicine, General & Internal

Towards precision medicine in lymphoid malignancies

Marco M. Buhler et al.

Summary: Histopathologic examination is important for the diagnosis of lymphoid malignancies, but recent advances in high-throughput technologies have improved our understanding of these tumors. Certain genomic alterations can provide diagnostic information and others can indicate prognosis or treatment response. Comprehensive molecular profiling may pave the way for precision diagnostics and medicine.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Hematology

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Rahul Lakhotia et al.

Summary: This study analyzed the dynamics of circulating tumor DNA (ctDNA) in patients with mantle cell lymphoma (MCL) following induction therapy. The results showed that patients with negative ctDNA after induction had longer survival, suggesting the potential of ctDNA as a prognostic biomarker. This supports further investigation into the use of ctDNA for response-adapted strategies in MCL.

BLOOD ADVANCES (2022)

Review Oncology

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

Eliza M. Lauer et al.

Summary: Circulating tumor DNA (ctDNA) profiling is a potential strategy for managing B-cell lymphoma patients. ctDNA assessment has advantages over conventional tissue biopsies as it captures the entire mutational landscape of tumors. This review provides a comprehensive overview of ctDNA detection and genotyping technologies in B-cell lymphoma, highlighting the advantages, limitations, and recent advances in sensitivity and accuracy. The potential applications of ctDNA in clinical practice and translational research are also discussed.

LEUKEMIA (2022)

Article Hematology

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

Vincent Camus et al.

Summary: The study demonstrates the significance of ctDNA analysis as a liquid biopsy and minimal residual disease tool in the management of cHL patients. By using a targeted NGS panel for fast analysis and monitoring the changes in ctDNA after chemotherapy, it helps to assess early treatment response and genetic features of cHL.

HAEMATOLOGICA (2021)

Article Pathology

Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice

Adam R. Davis et al.

Summary: This study reports on the empirical application of a targeted 40-gene panel in mature lymphoid neoplasms, with over 500 cases submitted for massively parallel sequencing (MPS) generating reportable results in 471 cases. Disease-associated variants (DAVs) were detected in 241 cases (51.2%), with the most frequent DAVs affecting TP53, CREBBP, MYD88, TNFRSF14, TNFAIP3, B2M, and NOTCH2. The findings confirm what is reported in the scientific literature and demonstrate the technical viability and utility of targeted MPS panels in routine clinical practice.

MODERN PATHOLOGY (2021)

Letter Oncology

Genetic complexity impacts the clinical outcome of follicular lymphoma patients

Maria Garcia-Alvarez et al.

BLOOD CANCER JOURNAL (2021)

Article Hematology

Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma

Sarah Haebe et al.

Summary: The study found that B-cell receptor subclones were shared between the two tumor sites in some patients with follicular lymphoma, while in many patients, the disease had evolved separately with limited tumor cell migration between the sites. Differences in tumor gene expression and cell surface protein profiles were observed in patients with divergent BCR evolution. Additionally, a specific correlation was detected between site-to-site tumor heterogeneity and T follicular helper (Tfh) cell abundance.
Article Hematology

Treating lymphoma is now a bit EZ-er

Ryan D. Morin et al.

Summary: Tazemetostat is the first epigenetic therapy approved for the treatment of FL, targeting the EZH2 histone methyltransferase. This review discusses the functional role of EZH2 mutations in lymphomagenesis and the development path of tazemetostat. Clinical data and ongoing research into EZH2 and tazemetostat in lymphomas from the germinal center suggest potential future therapeutic applications.

BLOOD ADVANCES (2021)

Article Biotechnology & Applied Microbiology

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

David M. Kurtz et al.

Summary: PhasED-seq improves the sensitivity of ctDNA detection by using multiple somatic mutations in individual DNA fragments, outperforming previous methods with better limits of detection in the ppm range. In patients with B cell lymphomas, PhasED-seq can detect more cases of ctDNA positivity associated with worse outcomes. The method is also applicable to solid tumors.

NATURE BIOTECHNOLOGY (2021)

Article Oncology

Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Alfredo Rivas-Delgado et al.

Summary: The study analyzed the utility of cfDNA in DLBCL patients to determine mutational profile and tumor burden. It found that higher levels of ctDNA were associated with clinical parameters and treatment response in DLBCL patients.

CLINICAL CANCER RESEARCH (2021)

Article Multidisciplinary Sciences

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

Julia Gonzalez-Rincon et al.

PLOS ONE (2019)

Article Medicine, General & Internal

Follicular lymphoma

Antonino Carbone et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Review Biochemistry & Molecular Biology

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations

Koorosh Korfi et al.

EPIGENETICS (2017)

Article Medicine, General & Internal

Genetic landscape and deregulated pathways in B-cell lymphoid malignancies

R. Rosenquist et al.

JOURNAL OF INTERNAL MEDICINE (2017)

Article Oncology

2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes

Lauren R. Teras et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

Article Medicine, General & Internal

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

Robert Kridel et al.

PLOS MEDICINE (2016)

Article Cell Biology

Genetics of Follicular Lymphoma Transformation

Laura Pasqualucci et al.

CELL REPORTS (2014)

Review Medicine, General & Internal

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Stephen M. Ansell et al.

MAYO CLINIC PROCEEDINGS (2012)

Letter Oncology

EZH2 Y641 mutations in follicular lymphoma

C. Boedoer et al.

LEUKEMIA (2011)

Article Multidisciplinary Sciences

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Ryan D. Morin et al.

NATURE (2011)